Review of teriflunomide and its potential in the treatment of multiple sclerosis
Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Dep...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-05-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/review-of-teriflunomide-and-its-potential-in-the-treatment-of-multiple-a3170 |
| _version_ | 1818407757714292736 |
|---|---|
| author | Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. |
| author_facet | Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. |
| author_sort | Clemens Warnke |
| collection | DOAJ |
| description | Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USAAbstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugs |
| first_indexed | 2024-12-14T09:32:55Z |
| format | Article |
| id | doaj.art-fd84723399604573b06e092ab975204f |
| institution | Directory Open Access Journal |
| issn | 1176-6328 1178-2021 |
| language | English |
| last_indexed | 2024-12-14T09:32:55Z |
| publishDate | 2009-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-fd84723399604573b06e092ab975204f2022-12-21T23:08:01ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212009-05-012009default333340Review of teriflunomide and its potential in the treatment of multiple sclerosisClemens WarnkeGerd Meyer zu HörsteHans-Peter HartungOlaf Stüveet al.Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USAAbstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugshttp://www.dovepress.com/review-of-teriflunomide-and-its-potential-in-the-treatment-of-multiple-a3170 |
| spellingShingle | Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis Neuropsychiatric Disease and Treatment |
| title | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_full | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_fullStr | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_full_unstemmed | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_short | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_sort | review of teriflunomide and its potential in the treatment of multiple sclerosis |
| url | http://www.dovepress.com/review-of-teriflunomide-and-its-potential-in-the-treatment-of-multiple-a3170 |
| work_keys_str_mv | AT clemenswarnke reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT gerdmeyerzuhampoumlrste reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT hanspeterhartung reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT olafstampuumlve reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT etal reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis |